Published online Mar 21, 2015. doi: 10.3748/wjg.v21.i11.3223
Peer-review started: November 23, 2014
First decision: December 26, 2014
Revised: January 16, 2015
Accepted: February 11, 2015
Article in press: February 11, 2015
Published online: March 21, 2015
Core tip: Nonalcoholic fatty liver disease (NAFLD) is not a single disease, but encompasses a spectrum of diseases and this makes it very difficult to find highly specific and sensitive biomarkers. We should therefore aim to find relevant prognostic markers rather than accurate diagnostic markers which will help to minimize the frequency of liver biopsies to evaluate disease progression. There is no evidence that biopsy and detailed staging of NAFLD is important in the NAFLD management and benefits patients. Finally, there is no evidence based treatment for NAFLD other than management of ‘metabolic syndrome’ by pharmacological or non-pharmacological (lifestyle management/surgical) approaches.